In the cervical cancer expansion cohort of a clinical trial for a novel Nectin-4-targeting ADC, the detection rate of Nectin-4 expression was 89.67%, and the detection rate of Nectin-4 tumor cell staining intensity of 3+ was 67.82% (Zhai et al., 2024). This evidence concerns the gene NECTIN4 and cervical carcinoma.